Company
Biotech set up to commercialise the University of Queensland's Molecular Clamp vaccine platform
Every investor coverage indicates participated in a round Vicebio raised.
Companies Vicebio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Vicebio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.